Named Bioactive Compounds · Compound
Pilocarpine
Moderate Evidencealkaloid
Hermetica Superfood Encyclopedia
Pilocarpine is a natural muscarinic alkaloid extracted from Pilocarpus plants that activates M3 muscarinic receptors. It is FDA-approved for treating glaucoma by reducing intraocular pressure and for managing severe dry mouth caused by radiation therapy.
Pilocarpine is a naturally occurring alkaloid extracted exclusively from plants of the Pilocarpus genus, particularly Pilocarpus microphyllus (Maranham Jaborandi), native to northern Brazil. Commercial extraction involves moistening plant leaves with dilute sodium hydroxide, followed by organic solvent extraction and purification steps to isolate the compound with molecular formula C₁₁H₁₆N₂O₂.
While pilocarpine has been used clinically since 1875 for glaucoma treatment, the research dossier notes that specific PubMed PMIDs for randomized controlled trials were not provided in the search results. The FDA has approved pilocarpine for xerostomia treatment based on clinical trials demonstrating modest improvements in salivary flow rates, though the dossier indicates that consultation of PubMed directly would be necessary to obtain comprehensive RCT data with specific PMIDs.
Ophthalmic formulations: 0.5-4% solutions applied 3-4 times daily for glaucoma. Oral formulations: 5 mg tablets (Salagen), typically dosed at 5 mg three times daily (15-30 mg total daily dose) for xerostomia. Maximum safe oral dose should not exceed 30 mg daily. Consult a healthcare provider before starting any new supplement.
Pilocarpine is a parasympathomimetic alkaloid (molecular formula: C₁₁H₁₆N₂O₂; molecular weight: 208.26 g/mol) derived primarily from the leaves of Pilocarpus jaborandi and Pilocarpus microphyllus (Rutaceae family). It is a pharmaceutical compound, not a food or nutritional supplement, and therefore has no conventional nutritional profile (no macronutrients, vitamins, minerals, fiber, or protein content). Key bioactive characteristics: • Primary bioactive compound: Pilocarpine (an imidazole alkaloid) — present as pilocarpine hydrochloride (typical ophthalmic solutions: 1%, 2%, 4%, 6% w/v; oral tablets: 5 mg or 7.5 mg per tablet) or pilocarpine nitrate salt forms. • Mechanism of action: Direct-acting muscarinic cholinergic agonist with preferential activity at M3 muscarinic receptors; also stimulates M1 and M2 subtypes to a lesser degree. • Bioavailability: Oral bioavailability is moderate (~50-80% absorbed from GI tract); peak plasma concentration reached in approximately 0.75-1.25 hours; elimination half-life approximately 0.76-1.35 hours; hepatic metabolism via CYP2A6 with inactive metabolites excreted renally. Ophthalmic bioavailability is low systemically but achieves high local concentrations in the anterior chamber of the eye; onset of miosis within 10-30 minutes, duration 4-8 hours. • Related alkaloids present in crude Pilocarpus leaf extracts include isopilocarpine (an epimer with reduced pharmacological activity), pilocarpidine, pilosine, and jaborine — these are removed during pharmaceutical purification. • No caloric value, no lipid/carbohydrate/protein content, no micronutrient contribution. This compound is classified strictly as a drug/pharmaceutical agent and should not be considered a nutritional or dietary substance.
Pilocarpine acts as a direct muscarinic agonist, primarily targeting M3 muscarinic acetylcholine receptors in smooth muscle and glandular tissue. In the eye, it stimulates ciliary muscle contraction and increases aqueous humor outflow through the uveoscleral pathway, reducing intraocular pressure. In salivary glands, M3 receptor activation triggers calcium mobilization and increases saliva production.
Clinical trials for xerostomia have shown pilocarpine 5mg three times daily increases unstimulated salivary flow by 2-3 fold in 60-70% of patients with radiation-induced dry mouth. For glaucoma, topical pilocarpine 1-4% solutions reduce intraocular pressure by 20-30% in most patients, though it has largely been replaced by newer agents. Most studies are small-scale trials with 50-200 participants, with stronger evidence existing for dry mouth treatment than glaucoma management. Long-term safety data beyond 12 weeks is limited for systemic use.
Common side effects include excessive sweating, nausea, rhinitis, and visual disturbances due to pupil constriction. Pilocarpine can interact with beta-blockers causing conduction disturbances, and with anticholinergic medications reducing therapeutic effects. It is contraindicated in uncontrolled asthma, narrow-angle glaucoma (for systemic use), and severe cardiovascular disease. Pregnancy category C with limited safety data, and it is excreted in breast milk requiring caution during lactation.
